Skip to main content
. 2022 Mar;22(1):648–656. doi: 10.4314/ahs.v22i1.75

Table 3.

NAFLD(+) p*
Lean PCOS 11 (27.5%) 0.041
Control 3 (8.8%)
Overweight /
obese
PCOS 26 (60.5%) 0.118
Control 19 (79.2%)

Comparison of non-alcoholic fatty liver disease (NAFLD) presence between polycystic ovary syndrome and control groups in lean (body mass index [BMI ≤ 25]) participants and overweight/obese (body mass index > 25]) participants. All lean patients had a fatty liver index lower than 30.

*

Chi-square test.

NAFLD (+): NAFLD is diagnosed with USG